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Summary The chromosomal region 10q23-24 is frequently deleted in a number of tumour types, including prostate adenocarcinoma and
glioma. A candidate tumour-suppressor gene at 1Oq23.3. designated PTENor MMAC1, with putative actin-binding and tyrosine phosphatase
domains has recently been described. Mutations in PTEN have been identified in cell lines derived from gliomas. melanomas and prostate
tumours and from a number of tumour specimens derived from glial. breast, endometrial and kidney tissue. Germline mutations in PTEN
appear to be responsible for Cowden disease. We identified five PTEN mutations in 37 primary prostatic tumours analysed and found that
70% of tumours showed loss or alteration of at least one PTEN allele. supporting the evidence for PTEN involvement in prostate tumour
progression. We raised antisera to a peptide from PTEN and showed that reactivity occurs in numerous small cytoplasmic organelles and that
the protein is commonly expressed in a variety of cell types. Northem blot analysis revealed multiple RNA species: some arise as a result of
altemative polyadenylation sites. but others may be due to altemative splicing.
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A number of chromosomal regions are frequently deleted in
prostate tumours. sugaesting that such loci harbour genes that
suppress tumour dexelopment or progression. In particular. consis-
tent losses at 8p. 16q and 10q haxe been observed (reviewed in
Cannon-Albright and Eeles. 1995). Usinc fluorescence-based
allelot-vping. we prexiousIv identified a 9-cM interval at the
lOq23/24 boundarv that is deleted in most prostate tumours (Grav
et al. 1995). Recentlv a candidate tumour-suppressor gene w-ith
putatixe actin-binding and tyrosine phosphatase domains has been
identified at 10q23.3 and designated PTEN (Li et al. 1997) or
MMACJ (Steck et al. 1997). Mutations in PTENhax-e been found in
tumour specimens derix ed from glial. breast. endometrial and
kidnev tissue (Rhei et al. 1997: Steck et al. 1997: Tashiro et al.
1997: Aanc et al. 1997) and in a number ofmelanoma(Guldberg et
al. 1997) and prostate adenocarcinoma cell lines (Li et al. 1997:
Steck et al. 1997). Germline mutations in PTEA have been identi-
fied in indixiduals "ith the autosomal dominant svndromes
Cow-den disease (multiple hamartoma syndrome) and Bannaxan-
Zonana sy-ndrome. These disorders confer a predisposition to
hamartomas at sexeral sites. including the breast and thyroid (Liaxx
et al. 1997) and macrocephalx. lipomas. intestinal hamartomatous
pol ps and vascular malformations (Marsh et al. 1997).
Here x e describe PTEN mutations in primary prostate tumours.
supporting exidence that PTEN may act as a tumour suppressor in
the prostate. In addition. Ae describe the generation of antipeptide
antibody- that detects PTEN inWestern blots and localizes it within
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the cell. The complex PTEN m_R.NA expression profile is also
analysed and discussed.
MATERIALS AND METHODS
Mutation analysis
Tumours and xenous blood samples wxere obtained from men
undergoing transurethral resection of the prostate. Tumour tissue
was microdissected from normal tissue and tumour and blood
DNA samples xxere prepared as described previously (Phillips et
al. 1994). Using primers based on intron sequences. PTEN exons
Aere amplified by polymerase chain reaction (PCR) from 30 ng of
tumour DNA under the follou-inc conditions: an initial 95-C
denaturing step of 2 min follou-ed by 30 cycles of 95 C for 30 s.
60 C for 30 s and 72 C for 30 s in a 50-jil reaction xolume. A 1-pA
aliquot of product xxas then used to seed a second 15-cxcle reac-
tion using M13-21 tailed primers to facilitate dye-primer
sequencing. After purification by passage through a Centricon-100
column (Amicon). exons were sequenced using a PRISM M13-21
dye-primer cycle sequencing system (Applied Biosystems).
Mutations were confirmed by sequencing a second independently
generated PCR product and comparinc tumour-derixved sequence
x ith that obtained from matched blood DNA.
Northern analysis
A multiple-tissue Northern blot (Clontech) was hybridized with a
random-prime labelled cgel purified insert from PTEN IMAGE
consortium (Auffrav et al. 1995) cDNA clone 264611 (Research
Genetics) at high stringency in ExpressHN-b hybridization solution
IClontech) in accordance with the supplier's instructions. A
Northern blot consisting of mRNA from the lymphoblastoid cell
line BRISTOL8 (BR18: Snarx et al. 1974) xxas hxbridized x-ith
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Table 1 PTENmutations in prostate tumours
Tumour stagea Tumour gradeb 10q allele loss Mutation Location
T4 M1 3 Yes insT: normal: AGT-AAG Exon 5
mutant: AGTTAAG
T3 M1 3 No delG: normal: TGGGATT Exon 2
mutant: TGG-ATT
T4 M1 2 Yes delTACT: normal: TAGTACTTACTTT Exon 8
mutant: TAG----TACTTT
T2 Ml 3 Yes Complex: normal: GCAGAAAGACTTGAAG--GCGTATACA Exon 2
mutantc: GCAGAAAGACTTGAAGacagaaagACA
T3 MO 3 No delT: normal: GCTTCTCTTTTTTTTCTGTCCACCAG Intron E (12 bp upstream
mutant: GCTTCTCTTTTTTT-CTGTCCACCAG of splice site)
aStaging is based on digital rectal examination and bone scan. Four of the five tumours show metastasis (Ml). bWHO gradings: 1, well differentiated; 2,
moderately differentiated; 3, poorly differentiated; 4, mixture of differentiation. cThe sequence in bold type appears to have duplicated and inserted downstream
(lowercase type), giving an overall insertion of 2 bp.
individual PCR-amplified PTEN exons 1, 6 and 8, a 120-bp frag-
ment derived from the PTEN 5' untranslated region (UTR) and a
239-bp fragment from the 3'-UTR beyond the first polyadenylation
signal, all at low stringency. Primer sequences for amplification of
the 5'-UTR fragment were 5'-GGTCTGAGTCGCCTGTCACC-3'
and 5'-TTAAAACCGGCCCGGGTCCC-3'; primers for amplifica-
tion of the 3'-UTR fragment were 5'-GACATTCGAGGAATTG-
GCCGC-3' and 5'-CAAGCCCATTCTTGTTGATAGCC-3'. PCR
was performed under the conditions described above. Probes were
generated by subsequent reamplification of 5 ng of PCR product
for 11 rounds of940C for 1 min, 50°C for 1 min and 72°C for 1 min
in the presence of30 gCi of[x--32P]dCTP (Hirst et al, 1992).
Polyclonal antibody preparation, Western blotting and
immunofluorescence
A peptide of 19 residues from amino acid positions 342 to 360
(sequence KVKLYFTKTVEEPSNPEAS) was synthesized and
conjugated to keyhole limpet haemocyanin (KLH) using
glutaraldehyde, 2 mg of peptide to 2 mg of protein (Coligan et al,
1994). Rabbits were immunized with the conjugate, 100 lg per
immunization, in complete Freund's adjuvant on the first occasion
and then on five subsequent occasions in incomplete Freund's
adjuvant; the immunizations were at 2-week intervals. Antibody
levels were determined by enzyme-linked immunosorbent assay
(ELISA) using peptide conjugated to bovine serum albumin (BSA)
and the specificity confirmed by Western blotting on bacterially
expressed PTEN. Western blots were carried out on total cell
lysates dissolved in SDS-PAGE sample buffer. Proteins were visu-
alized using an alkaline phosphatase-based chemiluminescence
system (Tropix, Applied Biosystems) and sized using BioRad low-
molecular-weight standards. Immunfluorescence was performed
with antibody that had been purified by protein A chromatography
to reduce the non-specific cell-surface fluorescence found in the
serum prior to immunization. FITC-conjugated sheep anti-rabbit
IgG was used as a second antibody and immunofluorescent
staining was visualized using a confocal microscope.
RESULTS
Thirty-seven primary prostate tumours, ofwhich 24 had previously
shown allele loss at lOq23.3 (Gray et al, 1995; ICG unpublished
data), were assessed for mutations in all nine PTEN exons (Steck
et al, 1997) by direct sequencing following PCR amplification. Five
mutations were identified (Table 1), four of which result in a trun-
cated protein, supporting the hypothesis that PTEN is a prostate
tumour-suppressor gene. Four of the mutations cause frameshifts
(two deletions, one insertion and a complex combined deletion/
duplication event). The remaining mutation is a small intronic dele-
tion close to an intron/exonjunction and which may cause aberrant
splicing by reducing the length of the splice acceptor polypyrimi-
dine tract (Shapiro and Senapathy, 1987). None of these mutation
events was detected in matched blood samples and they therefore
must have arisen somatically in the tumour.
Four intronic variants were also detected, each being present in
both tumour and blood DNA: a single-base A-*G substitution in
intron A 96 bp upstream ofexon 2; a4-bpTTTG deletion in intron
B 23 bp upstream of exon 3; a 5-bp ATCTT insertion in intron D
110 bp downstream ofexon 4, and aT insertion also in intron D 28
bp upstream ofexon 5. The allele with the 5-bp insert was found at
a frequency of 39/74 in the 37 individuals studied. The remaining
variants were less common, each being identified only once.
When used to probe a multiple-tissue Northern blot (Clontech),
PTEN cDNA clone 264611 (Auffray et al, 1995), comprising
exons 1-7 plus 478 bp of 5' untranslated DNA (IC Gray, unpub-
lished data), hybridizes to at least five bands common to all tissues
tested with varying relative band intensities in each tissue type
(Figure Ia). However, when a 120-bp fragment from the PTEN5'-
UTR was used to probe a similar blot, a single band of approxi-
mately 5.5 kb was identified in all tissues (Figure lb). To
determine further the relationship between the different tran-
scripts, mRNA from the lymphoblastoid cell line BRI8 (Snary
et al, 1974) was hybridized with probes derived from the PTEN
5'-UTR and with individual PTEN coding exons 1, 6 and 8. The
5'-UTR probe identified the expected 5.5-kb band observed with
the multiple-tissue Northern blot (Figure lci). Probes derived from
PTEN exons 1, 6 and 8 each gave a similar profile to the longer
cDNA probe, with a 2.4-kb band consistently generating the
strongest signal (Figure lcii).
Examination of overlapping PTEN expressed sequence tags in
the GenBank database suggests that a less intense 2.7-kb band
(Figure la) represents an extension of the 2.4-kb species, the
former having 300 bp of extra 3' untranslated sequence owing to
the use of an alternative polyadenylation signal. Consistent with
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Figure 2 Westem bot of a number of cell lines probed with rabbit
antserum to the C-terminal peptide of PTEN. POC+15 is an
adenocarcinoma line from colon, MOLT4 a T4yrrphoblastoid line, HACAT an
epithelial cell line, MKN45 a gastric' carcinoma cell line, BRISTOL8 a B-
lymph toid cell line and HCT116 a colorectal carcinoma cell line. The
predicted size of the PTEN protein (48.2 kDa) is indicated with an arrow
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Figure 1 PTEN expression profile in a range of human tissues. (A) Labelled
IMAGE cONA clone 264611 (Auffray et al, 1995), cornising of PTENexons
1-7 plus 478 bp of 5' untralated DNA (IC Gray, unpublished data), gives a
similar expression pattem of at last five wansrpts ranging from 2.4 to
5.5 kb in all tbssues. Relative band intensities appear to vary between tissues.
(B) A probe derived from the PTEN5' untrasated region detects a single
5.5-kb tanscript in all tissues tested. (C) PTENexpression in the
lymphobtoid cell line BR18. Arrows show the migration postions of 18 and
28S rbosomal RNA- (i) The 5'-UTR probe detects the expected 5.5-kb
tanscript on a blot of BR18 mRNA- (ii) A probe derived from PTEN exon 6
gives a similar profile to that seen with the longer coDNA probe in (A) above,
with the 2.4-kb band giving the stongest signal. Identical patterns were
produced with exons 1 and 8 (not shown). (ini) A probe from the PTEN 3'-UTR
downstream of the first polyadenyiation signal does not hybridze to the 2.4-
kb transcnpt but detects the others, suggestng that the 2.4-kb mRNA uses
this proximal polyadenylation site, whereas the ofters do not
Fgue 3 Immunofluorcence staining of the DU145 pstate carcinoma
cell line with anti-PTEN peptide rabbit antiserum. (A) Cells Labelled with anti-
PTEN antibody and (B) cell labelled with normal rabbit antibody. The figure in
the top comer represents the distance from the slide that the photograph was
taken
this. aprobe derived from this extra 3' sequence does not hybridize
to the 2.4-kb transcript. but detects the others from 2.7 to 5.5 kb
(Figure Iciii).
Two peptides were used to immunize rabbits. but only the most
C-terminal of the two (amino acids 342-360) produced an anti-
body response. The other peptide. a 22-amino-acid sequence from
position 219 to 240. did not induce an anti-PTEN response.
although a good anti-carrier (anti-KLH) response was given. On
Westem blots the antiserum to the C-ternminal peptide bound to a
protein with an apparent molecular weight of 54.8 kDa. close to
the predicted molecular weight from the PTEN amino acid
sequence (48.2 kDa). Several cell lines gave an identical pattem
(Figure 2). Immunofluorescence ofpermeabilized cells suggested
that the antipeptide antibody binds to a small particulate structure
within the cytoplasm ofthe cell (Figure 3).
DISCUSSION
Although the identification of PTEN mutations in primary prostate
tumours provides good evidence that PTEN is a prostate tumour-
suppressor gene. the numberofmutations detected is far lowerthan
expected (5/37) given that nearly 70% of prostate tumours show
loss of the 10kq23.3 region (Gray et al. 1995: IC Gray. unpublished
data). There are several possible explanations. Sequencing as a
method ofmutation detection is unlikely to be 100% efficient. The
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nature of prostate tumour gro%vth with a lack of normal tumour
boundary makes it difficult to be certain about the level of normal
tissue contamination of the dissected tumour. Furthermore. w-here
functional loss is associated with the later stages oftumourprogres-
sion. as appears to be the case here. there may be clonal subpopula-
tions of tumour that do not cam- the mutation. In addition. gross
deletions spanning one or more exons and mutations in regulatonr
sequences outside the coding region would have gone undetected.
Alternatively. there is the possibilitv that mutation or loss of a
single PTEiN allele may be sufficient for a tumour growth advan-
ta2e: our analysis showed three tumours with loss of one PTEN
allele and a mutation in the second. 21 with loss ofone PTEN allele
but no detectable mutation in the second and t-o with one mutant
allele but no detectable loss ofthe second. In summanr. 26 tumours
of a total of 37 (70%s) had alteration or loss of at least one copy of
PTE.N. During preparation of this manuscript. a report appeared in
the literature describing inactivation of both PTEN alleles in 10 of
80 primary prostate tumours studied (Caims et al. 1997). providing
further evidence that PTEN is a prostate tumour suppressor gene.
Furthermore. prostate cancerhas been identified in association with
Cowden disease (Inaaaki and Ebisuno. 1996). which has recentlv
been shown to be caused by aermline PTEN mutations (Liaw et al.
1997). However. the possibility of a further tumour-suppressor
gene at I10q23.3 cannot be excluded.
PTENV appears to be expressed in a wide range ofcell types: this
is evident from the ubiquitous expression of the mRNA in all
tissues examined and from the presence ofthe protein in cells from
several different origns. The anti-PTEN antibody indicates that
PTEN is found associated with small cytoplasmic particles. an
obsen-ation in keepincg with data describinc the direct v-isualization
of expressed PTEN protein with the Flag epitope (Li and Sun.
1997).
A complex pattern of transcripts w-as found for PTEN in all
tissues tested. similar to the profiles previously reported by- Steck
et al (1997). Although some of the transcript profile may be
accounted for by alternati-e polvadenylation sites. other differ-
ences are also evident. suggesting alternative PTEN splicingr or
cross-hybridization of PTE.N with mRNA species of distinct but
related sequence. raising, the possibility that PTEN may be a
member of a wider gene family. There appear to be at least two
discrete major PTEV transcripts with 5' sequence differences.
Recently. an expressed PTEN pseudogene on chromosome 9
has been identified (Kim et al. 1998: Teng et al. 1998). Cross-
hybridization to RNA derived from this pseudogene may therefore
account for some ofthe PTEN transcript profile.
The broad spectrum of tumour types showing PTE,N' mutations
(Li et al. 1997: Steck et al. 1997). coupled with apparently ubiqui-
tous expression. suggests that PTEV has a role in the progression
ofa significant proportion oftumours derived from a diverse range
of tissues. The identification of germline mutations in individuals
suffering from Cowden disease (Liaw et al. 1997) raises the possi-
bility that low-penetrance germline PTEN lesions may be respon-
sible for some breast (and other) cancers previously thought to be
sporadic. As four of the five mutations descnrbed here were
detected in late-stage tumours showinr metastasis (Table 1). PTEN
inactivation may be involved in a pathway leading to metastatic
potential: a recent analy-sis of metastatic prostate cancer tissues
also implicates PTE,\T involvement in metastasis (Suzuki et al.
1998). Therefore. it could pro-e to be a useful marker for moni-
toring prostate tumour progression and provide information that
will assist in making therapeutic decisions.
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